Loading stock data…
SVRA
$5.30+0.18 (+3.52%)
Market ClosedLast close May 4
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Savara Inc. in the Healthcare sector is trading at $5.30. The stock is currently 24% below its 52-week high of $7.00, remaining 12.8% above its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why SVRA maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 35) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.30
Potential Upside
5%
Whystock Fair Value$5.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.05B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.31
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-19.28%
Volume
Today's trading volume
1.03M
Recent News
US High Growth Tech Stocks To Watch
The United States market remained flat over the last week, yet it has experienced a 30% rise over the past 12 months with earnings forecasted to grow by 16% annually. In this context of robust growth potential, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability to capitalize on emerging opportunities.
Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim
Why the FDA Review Extension Matters for Savara Stock Savara (SVRA) shares are reacting to news that the FDA has extended the Priority Review of its molgramostim biologics license application for autoimmune pulmonary alveolar proteinosis by three months, shifting the target action date to November 22, 2026. See our latest analysis for Savara. The FDA extension has arrived after a mixed stretch for the share price, with a 1 day share price return of 3.64% following recent weakness. At the same...
High Growth Tech Stocks To Watch In The US March 2026
The United States market remained flat over the last week but has risen 16% over the past year, with earnings projected to grow by 16% annually in the coming years. In light of these conditions, identifying high growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability to capitalize on evolving technological trends.
VR Adviser Adds Over 1 Million Savara Shares
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.
Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed
Savara Inc. recently announced that the FDA has accepted for review its Biologics License Application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis, granting Priority Review with a PDUFA action date of August 22, 2026. This filing adds to MOLBREEVI’s existing Fast Track, Breakthrough Therapy, Orphan Drug, Innovation Passport, and Promising Innovative Medicine designations, underscoring its potential importance for a rare respiratory disease with limited treatment...